Emerging treatment approaches for myeloma-related bone disease

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma

(2016) J. Delgado-Calle et al.   CANCER RESEARCH

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

(2016) N. S. Raje et al.   CLINICAL CANCER RESEARCH

The European Hematology Association Roadmap for European Hematology Research: a consensus document

(2016) A. Engert et al.   HAEMATOLOGICA

High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma

(2016) Fei Hu et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Periostin action in bone

(2016) Nicolas Bonnet et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

(2016) N Raje et al.   Blood Cancer Journal

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma

(2016) E Terpos et al.   Blood Cancer Journal

The European Hematology Association Roadmap for European Hematology Research: a consensus document

(2016) A. Engert et al.   HAEMATOLOGICA

Role of Periostin in Adhesion and Migration of Bone Remodeling Cells

(2016) Teresa Cobo et al.   PLoS One

Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site

(2015) Beom-Jun Kim et al.   BONE

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma

(2015) Timothy J Underwood et al.   JOURNAL OF PATHOLOGY

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma

(2015) R H Prabhala et al.   LEUKEMIA

LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease

(2015) Giacomina Brunetti et al.   Oncotarget

Sotatercept in patients with osteolytic lesions of multiple myeloma

(2014) Kudrat M. Abdulkadyrov et al.   BRITISH JOURNAL OF HAEMATOLOGY

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma

(2014) Zhen Ying Gan et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

(2014) Hui Jun Lim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Serum Periostin Is Associated With Fracture Risk in Postmenopausal Women: A 7-Year Prospective Analysis of the OFELY Study

(2014) J. C. Rousseau et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Colocalization of β-catenin with Notch intracellular domain in colon cancer: a possible role of Notch1 signaling in activation of CyclinD1-mediated cell proliferation

(2014) Natarajan Gopalakrishnan et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Periostin and its emerging role in systemic carcinogenesis

(2014) S. Kapoor   OSTEOPOROSIS INTERNATIONAL

Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation

(2014) G. T. Sakellariou et al.   RHEUMATOLOGY

Management of bone disease in multiple myeloma

(2014) Evangelos Terpos et al.   Expert Review of Hematology

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

(2013) Evangelos Terpos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis

(2013) Xiao-Xiang Chen et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimal use of bisphosphonates in patients with multiple myeloma

(2013) E. Terpos et al.   BLOOD

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

(2013) Samantha Pozzi et al.   BONE

The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Signaling Between Tumor Cells and the Host Bone Marrow Microenvironment

(2013) Natasa Kovacic et al.   CALCIFIED TISSUE INTERNATIONAL

The effects of bortezomib on bone disease in patients with multiple myeloma

(2013) Mohamad Mohty et al.   CANCER

Periostin and transforming growth factor β-induced protein (TGFβIp) are both expressed by osteoblasts and osteoclasts

(2013) Blandine Merle et al.   CELL BIOLOGY INTERNATIONAL

Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

(2013) Juliet McColm et al.   JOURNAL OF BONE AND MINERAL RESEARCH

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

(2013) Evangelos Terpos et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy

(2013) T Scullen et al.   LEUKEMIA

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT

(2013) E Terpos et al.   LEUKEMIA

International Myeloma Working Group recommendations for global myeloma care

(2013) H Ludwig et al.   LEUKEMIA

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo

(2013) J Glauer et al.   Blood Cancer Journal

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

(2012) E. Terpos et al.   ANNALS OF ONCOLOGY

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

(2012) G. J. Morgan et al.   BLOOD

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

(2012) Stuart A. Rushworth et al.   CELLULAR SIGNALLING

Activin receptor antagonists for cancer-related anemia and bone disease

(2012) Scott Z Fields et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sclerostin: a possible target for the management of cancer-induced bone disease

(2012) Maria Gkotzamanidou et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone

(2012) Farzin M Takyar et al.   JOURNAL OF BONE AND MINERAL RESEARCH

VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology

(2012) Richard M Taylor et al.   LABORATORY INVESTIGATION

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

(2011) Giacomina Brunetti et al.   Annals of the New York Academy of Sciences

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease

(2011) J. A. Fowler et al.   BLOOD

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

(2011) S. D'Souza et al.   BLOOD

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

(2011) J. Qian et al.   BLOOD

Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease

(2011) Evangelos Terpos et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

(2011) Michel Delforge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Functional Specialization of Interleukin-17 Family Members

(2011) Yoichiro Iwakura et al.   IMMUNITY

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

(2011) Gareth J Morgan et al.   LANCET ONCOLOGY

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

(2011) S Vallet et al.   LEUKEMIA

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

(2011) Tomoki Nakashima et al.   NATURE MEDICINE

Myeloma cells suppress osteoblasts through sclerostin secretion

(2011) S Colucci et al.   Blood Cancer Journal

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

(2010) E. Terpos et al.   ANNALS OF ONCOLOGY

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

(2010) R. H. Prabhala et al.   BLOOD

Tumor–host cell interactions in the bone disease of myeloma

(2010) Jessica A. Fowler et al.   BONE

Biochemical and molecular mechanisms of action of bisphosphonates

(2010) Michael J. Rogers et al.   BONE

CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth

(2010) Katia Beider et al.   EXPERIMENTAL HEMATOLOGY

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

(2010) M. Zangari et al.   HAEMATOLOGICA

Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases

(2010) Sylvain Contié et al.   INTERNATIONAL JOURNAL OF CANCER

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

(2010) Andrew D Chantry et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin antibody treatment enhances metaphyseal bone healing in rats

(2010) Fredrik Agholme et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

(2010) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

(2009) Michele Moschetta et al.   EUROPEAN JOURNAL OF CANCER

RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases

(2009) Evangelos Terpos et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Dickkopf-1: a suitable target for the management of myeloma bone disease

(2009) Maria Gavriatopoulou et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathogenesis and management of myeloma bone disease

(2009) Dimitrios Christoulas et al.   Expert Review of Hematology

The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology

(2009) Russell A. Norris et al.   Journal of Cell Communication and Signaling

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation

(2008) Mitsuru Futakuchi et al.   CANCER SCIENCE

Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals

(2008) Masahiro Shinohara et al.   CELL

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

(2008) A. Lipton et al.   CLINICAL CANCER RESEARCH

The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation

(2008) Seoung Hoon Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts

(2008) Elizabeth H Allan et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*

(2008) Jon Ruckle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA

Physiological, Pharmacological, and Nutritional Regulation of Circulating Adiponectin Concentrations in Humans

(2008) Michael M. Swarbrick et al.   Metabolic Syndrome and Related Disorders

Activins and activin antagonists in hepatocellular carcinoma

(2008) Alev Deli   WORLD JOURNAL OF GASTROENTEROLOGY

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

(2007) G. David Roodman et al.   CANCER TREATMENT REVIEWS